Cargando…

Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer

IMPORTANCE: Performing DNA genetic testing (DGT) for hereditary cancer genes is now a well-accepted clinical practice; however, the interpretation of DNA variation remains a challenge for laboratories and clinicians. Adding RNA genetic testing (RGT) enhances DGT by clarifying the clinical actionabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karam, Rachid, Conner, Blair, LaDuca, Holly, McGoldrick, Kelly, Krempely, Kate, Richardson, Marcy E., Zimmermann, Heather, Gutierrez, Stephanie, Reineke, Patrick, Hoang, Lily, Allen, Kyle, Yussuf, Amal, Farber-Katz, Suzette, Rana, Huma Q., Culver, Samantha, Lee, John, Nashed, Sarah, Toppmeyer, Deborah, Collins, Debra, Haynes, Ginger, Pesaran, Tina, Dolinsky, Jill S., Tippin Davis, Brigette, Elliott, Aaron, Chao, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820040/ https://www.ncbi.nlm.nih.gov/pubmed/31642931 http://dx.doi.org/10.1001/jamanetworkopen.2019.13900

Ejemplares similares

False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care
por: Tandy-Connor, Stephany, et al.
Publicado: (2018)

Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay
por: Farber-Katz, Suzette, et al.
Publicado: (2018)

Classification of the canonical splice alteration MUTYH c.934-2A > G is likely benign based on RNA and clinical data
por: Hernandez, Felicia, et al.
Publicado: (2022)

Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer
por: Yadav, Siddhartha, et al.
Publicado: (2020)

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients
por: LaDuca, Holly, et al.
Publicado: (2019)

Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes
por: Hu, Chunling, et al.
Publicado: (2018)

Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes
por: Pesaran, T., et al.
Publicado: (2016)

A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense-mediated mRNA decay
por: Krempely, Kate, et al.
Publicado: (2018)

Diagnosing hereditary cancer predisposition in men with prostate cancer
por: Pritzlaff, Mary, et al.
Publicado: (2020)

Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing
por: Horton, Carolyn, et al.
Publicado: (2023)

Mutation prevalence tables for hereditary cancer derived from multigene panel testing
por: Hart, Steven N., et al.
Publicado: (2020)

An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance
por: Iversen, Edwin S., et al.
Publicado: (2022)

Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients
por: LaDuca, Holly, et al.
Publicado: (2014)

Universal Multi Gene Panel Testing For Individuals With Pheochromocytomas And Paragangliomas
por: Horton, Carolyn, et al.
Publicado: (2021)

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
por: Shimelis, Hermela, et al.
Publicado: (2018)

Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort
por: Li, Hongyan, et al.
Publicado: (2019)

Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield
por: Horton, Carolyn, et al.
Publicado: (2022)

Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception
por: Bychkovsky, Brittany L., et al.
Publicado: (2023)

Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception
por: Bychkovsky, Brittany L., et al.
Publicado: (2023)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
por: Pritzlaff, Mary, et al.
Publicado: (2016)

The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort
por: Hu, Chunling, et al.
Publicado: (2020)

Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations
por: Horton, Carolyn, et al.
Publicado: (2022)

Somatic TP53 variants frequently confound germline testing results
por: Weitzel, Jeffrey N., et al.
Publicado: (2017)

Mutational and splicing landscape in a cohort of 43,000 patients tested for hereditary cancer
por: Horton, Carolyn, et al.
Publicado: (2022)

Correction: DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes
por: Richardson, Marcy E., et al.
Publicado: (2018)

DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes
por: Richardson, Marcy E., et al.
Publicado: (2018)

Avascular Necrosis of the Metacarpal Head: A Case of Dietrich’s Disease and Review of the Literature
por: McGoldrick, Niall P., et al.
Publicado: (2015)

Validation of a prostate cancer polygenic risk score
por: Black, Mary H., et al.
Publicado: (2020)

Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes
por: Landrith, Tyler, et al.
Publicado: (2020)

Genogramas en la evaluación familiar /
por: McGoldrick, Monica
Publicado: (1996)

catena-Poly[[[aquacopper(II)]-μ-(biphenyl-2,2′-dicarboxylato)-μ-[N,N′-bis(pyridin-4-yl)urea]] 1.25-hydrate]
por: Uzorka, Ben, et al.
Publicado: (2020)

Poly[[μ-1,3-bis(pyridin-3-yl)urea]bis(μ(4)-succinato)dicopper(II)], a ribbon-like coordination polymer
por: Ezenyilimba, Frederick, et al.
Publicado: (2023)

Poly[[aqua[μ(2)-1,3-bis(pyridin-4-yl)urea-κ(2) N (4):N (4′)]bis(μ(3)-5-tert-butylisophthalato-κ(3) O (1):O (1′):O (3))dizinc(II)] trihydrate], a double-strand coordination polymer
por: Jia, Jason, et al.
Publicado: (2023)

Poly[[μ-1,4-bis(pyridin-4-ylmethyl)piperazine]bis[μ(3)-4-(2-carboxylatoethyl)benzoato]dicopper(II)]
por: Jia, Jason, et al.
Publicado: (2023)

Poly[bis[μ(2)-1,3-bis(pyridin-4-yl)urea-κ(2) N (4):N (4′)]bis(μ(2)-5-methylisophthalato-κ(2) O (1):O (3))dizinc(II)], a parallel interpenetrated slab-like coordination polymer with {3.6(4)8}{3(2)6.7(2)8} 4,4-connected binodal topology
por: Jia, Jason, et al.
Publicado: (2023)

Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance
por: Richardson, Marcy E., et al.
Publicado: (2021)

Comercialización y venta de servicios financieros
por: McGoldrick, Peter J.
Publicado: (1996)

Complications of regional anesthesia for ophthalmic surgery.
por: McGoldrick, K. E.
Publicado: (1993)

Bis(dimethylmalonato-κ(2) O,O′)bis[4-(4-pyridylamino-κN (4))pyridinium]nickel(II) hexahydrate
por: Farnum, Gregory A., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_48q64982ctkhdh9bjl28d57lik